PF 3084014 hydrobromide is a highly potent and selective γ-secretase inhibitor belonging to the azacycle compound class, with an IC₅₀ of 1.2nM[1]. As a transmembrane aspartyl protease complex, γ-secretase primarily functions to cleave type I transmembrane proteins such as Notch receptors and amyloid precursor protein, thereby regulating cellular processes including proliferation, differentiation, and apoptosis[2]. By inhibiting γ-secretase activity, PF 3084014 hydrobromide has demonstrated antitumor efficacy in models of hematological cancers, breast cancer, colorectal cancer, and pancreatic cancer[3].
In vitro, treatment with PF 3084014 hydrobromide (0–10μM) for 48 hours inhibited the growth of all prostate cancer cells (Du145, PC3, Du145R, and PC3R) and induced a dose-dependent reduction in the Notch pathway activation marker, Notch-1 receptor intracellular domain (NICD)[4]. When 97H and Huh7 cells were treated with PF 3084014 hydrobromide (0.5–2μM) for 48 hours, the drug downregulated cancer stem cell (CSC) markers (CD90⁺, EpCAM⁺) and stemness-related gene expression in hepatocellular carcinoma cells by inhibiting the Notch signaling pathway, significantly reducing sphere formation and proliferation capacity[5].
In vivo, PF 3084014 hydrobromide (120mg/kg) demonstrated significant antitumor efficacy in a breast cancer mouse model with MDA-MB-231Luc cells xenografts through multiple mechanisms, including inducing cell apoptosis, inhibiting cancer stem cell self-renewal, suppressing proliferation, and anti-angiogenesis[6]. Additionally, oral administration of PF 3084014 hydrobromide (125mg/kg) in colorectal cancer xenograft mice significantly reduced invasive tumor lesions and tumor volume[7].
References:
[1] Lanz TA, Wood KM, Richter KE, et al. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. J Pharmacol Exp Ther 2010, 334(1):269-277.
[2] Yabuuchi S, Pai SG, Campbell NR, et al. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 2013, 335(1):41-51.
[3] Samon JB, Castillo-Martin M, Hadler M, et al. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2012, 11(7):1565-1575.
[4] Cui D, Dai J, Keller JM, et al. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Clinical Cancer Research 2015, 21(20):4619-4629.
[5] Wu CX, Xu A, Zhang CC, et al. Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1–Stat3. Molecular Cancer Therapeutics 2017, 16(8):1531-1543.
[6] Zhang CC, Pavlicek A, Zhang Q, et al. Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models. Clinical Cancer Research 2012, 18(18):5008-5019.
[7] Arcaroli JJ, Quackenbush KS, Purkey A, et al. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model. Br J Cancer 2013, 109(3):667-675.
PF 3084014 hydrobromide是一种高效且高选择性的γ-分泌酶抑制剂，属于氮杂环类化合物，其IC₅₀为1.2nM[1]。γ-分泌酶作为一种跨膜天冬氨酸蛋白酶复合物，主要功能是切割 Notch 受体、淀粉样前体蛋白等Ⅰ型跨膜蛋白，进而调控细胞的增殖、分化及凋亡过程[2]。PF 3084014 hydrobromide通过抑制 γ-分泌酶活性，在血液癌、乳腺癌、结直肠癌和胰腺癌模型中显示出抗肿瘤功效[3]。
在体外，使用PF 3084014 hydrobromide（0-10μM）处理Du145、PC3、Du145R和PC3R细胞48h，可抑制所有前列腺癌细胞生长，并诱导Notch通路激活标志物Notch-1受体细胞间结构域（NICD）呈剂量依赖性降低 [4]。PF 3084014 hydrobromide（0.5-2μM）分别处理97H和Huh7细胞48小时，通过抑制Notch信号通路，下调肝癌细胞的CSC标志物（CD90⁺、EpCAM⁺）及干性基因表达，显著减少球形细胞的形成及增殖能力 [5]。
在体内，PF 3084014 hydrobromide（120mg/kg）在MDA-MB-231Luc细胞异种移植的乳腺癌小鼠模型中，通过诱导细胞凋亡、抑制癌症干细胞自我更新、抗增殖及抗血管生成等多种机制，展现出显著的抗肿瘤功效[6]。此外，PF 3084014 hydrobromide（125mg/kg）经口服给药于结直肠癌异种移植肿瘤小鼠，可显著减少浸润肿瘤病灶并缩小肿瘤体积[7]。